Document Type


Publication Date



A live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine was evaluated in healthy respiratory syncytial virus/parainfluenza virus type 3 seropositive children aged 1 to 9 years. Three cohorts of 40 children were randomized 1:1 to receive 104, 105 or 106 median tissue culture infectious dose50 MEDI-534 vaccine of placebo. The vaccine's safety profile was similar to placebo, no viral shedding was detected, and the vaccine was minimally immunogenic.


This article first appeared in the July 2009 issue of The Pediatric Infectious Disease Journal, and is reprinted with permission.

©2009 Wolters Kluwer Health